Moreover, IGF1R seems to be a direct target of sorafenib since the latter decreased its expression and phosphorylation by offsetting the insulin-like growth factor-1 binding to CLL cells and ultimately dropping the in vitro IGF1R kinase activity (62). The gene discussed is IGF1; the disease is B-cell chronic lymphocytic leukemia.